Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12259553 | 0.90 | ADORA1 (0.57) | ADORA2AADORA2BALDH1A1ADORA1MAOB | |
| SCHEMBL12256846 | 0.88 | ADORA2A (0.58) | ADORA2AADORA2BADORA1MAOB | |
| SCHEMBL8184575 | 0.87 | ADORA2A (0.54) | ADORA2AADORA2BKDM4EALDH1A1ADORA1 | |
| SCHEMBL12256472 | 0.84 | ADORA2A (0.45) | ADORA2AADORA2BADORA1MAOB | |
| SCHEMBL12257462 | 0.84 | ADORA2A (0.49) | ADORA2AADORA2BADORA1MAOB | |
| SCHEMBL4948213 | 0.82 | ADORA2A (0.56) | ADORA2AADORA2BADORA1MAOB | |
| SCHEMBL12257989 | 0.82 | ADORA2A (0.58) | ADORA2AADORA2BADORA1MAOB | |
| SCHEMBL12256832 | 0.82 | ADORA2B (0.48) | ADORA2AADORA2BMAOB | |
| SCHEMBL12257592 | 0.82 | ADORA2A (0.55) | ADORA2AADORA2BMAOB | |
| SCHEMBL12256755 | 0.82 | KDM4E (0.52) | ADORA2AADORA2BKDM4EALDH1A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044061-B2 | Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. | UCB PHARMA GMBH (DE) | 2011-10-25 | — | — | US | disclosed |
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221134-A1 | 8-ALKYNYLXANTHINES AND DERIVATIVES | SLC6A3, PARK7, SLC18A2 | ADORA2A 115/4885ADORA2B 279/4885KDM4E 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.